Literature DB >> 8443207

Coronary artery disease after heart transplantation: timing of coronary arteriography.

A H Balk1, M L Simoons, M J vd Linden, P J de Feyter, B Mochtar, W Weimar, E Bos.   

Abstract

The increasing numbers of long-term survivors after heart transplantation make yearly coronary arteriography, used by most centers to study the development of transplant coronary artery disease, less practical. Therefore the prevalence and clinical relevance of coronary artery disease in 119 one-year survivors of heart transplantation were studied. Visual analysis revealed two main patterns of vascular changes: abnormalities of the epicardial vessels and their major branches and abnormalities of the tertiary branches. The prevalence of all abnormalities in the coronary vascular tree increased from 34% after 1 year to 79% after 5 years. The prevalence of anatomically significant lesions (more than 50% stenosis in the epicardial branches or abrupt ending/proximal occlusion of tertiary branches) was only 11% after 5 years. During follow-up of 25 to 87 (median, 43) months, no significant coronary artery disease developed in the 101 patients who showed normal epicardial vessels or abnormal tertiary branches only at their first year angiography, and none of the patients died of ischemic heart disease. Of the 18 patients with abnormal epicardial vessels, three patients died of ischemic heart disease; one of these patients was treated with atherectomy and is alive at the moment of this report, and two patients showed progression of discrete lesions without evidence of ischemia until now. Based on these findings, a schedule for timing of arteriography was developed depending on the first-year coronary findings.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443207

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

1.  Effect of adopting a new histological grading system of acute rejection after heart transplantation.

Authors:  A H Balk; P E Zondervan; P van der Meer; T van Gelder; B Mochtar; M L Simoons; W Weimar
Journal:  Heart       Date:  1997-12       Impact factor: 5.994

2.  The frequency and avidity of committed cytotoxic T lymphocytes (cCTL) for donor HLA class I and class II antigens and their relation with graft vascular disease.

Authors:  N M van Besouw; E H Loonen; L M Vaessen; A H Balk; F H Claas; W Weimar
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

3.  Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.

Authors:  A H Balk; W Weimar; P H Rothbarth; K Meeter; H J Metselaar; B Mochtar; M L Simoons
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

4.  The development of transplant coronary artery disease after cardiac transplantation is correlated with a predominance of CD8+ T lymphocytes in endomyocardial biopsy derived T cell cultures.

Authors:  N H Jutte; K Groeneveld; A H Balk; A J Ouwehand; E H Loonen; M Van der Linden; S Strikwerda; B Mochtar; F H Claas; W Weimar
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

5.  Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern.

Authors:  Raymond L Benza; Matthew A Cavender; Joseph Barchue; Jose A Tallaj; Robert C Bourge; James K Kirklin; Christopher S Coffey
Journal:  J Heart Lung Transplant       Date:  2007-05       Impact factor: 10.247

6.  Cardiac allograft vasculopathy in Dutch heart transplant recipients.

Authors:  G Galli; K Caliskan; A H M M Balk; R van Domburg; O Birim; J Salerno-Uriarte; O C Manintveld; A A Constantinescu
Journal:  Neth Heart J       Date:  2016-12       Impact factor: 2.380

7.  Toxoplasma gondii serostatus is not associated with impaired long-term survival after heart transplantation.

Authors:  Jaap J van Hellemond; Ron T van Domburg; Kadir Caliskan; Ozcan Birim; Aggie H Balk
Journal:  Transplantation       Date:  2013-12-27       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.